Sponsor study identifier
Secondary identifiers
interventional
49
1 country
1
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2008
Actual (reported)Study Completion
Not reported
Date not reportedThe aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
December 28, 2007
Actual (reported)January 11, 2008
Actual (reported)May 2008
Actual (reported)Evaluate progression-free survival with capecitabine and interferon treatment in metastatic renal cell carcinoma (MRCC) patients (pts) with IL-2 failure in first-line
one year
Evaluate the safety and tolerability of the capecitabine and interferon combination
one year
Evaluate response rate and overall survival with the capecitabine and interferon combination in MRCC pts with progression on IL-2 based regimens
one year
All patients will receive capecitabine and interferon-alpha.
Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
capecitabine, interferon-alpha
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordN.N. Blokhin Russian Cancer Research Center
Moscow, 115478, Russia
Ilya V. Tsimafeyeu, MD
Kidney Cancer Research Bureau
Lev V. Demidov, MD, DSc.
N.N. Blokhin Russian Cancer Research Bureau
First Submitted
December 28, 2007
First Posted
January 11, 2008
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2008
Actual (reported)Contact the study team to confirm eligibility.
Last Updated
May 1, 2009
Record last verified: 2009-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: